Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.
Surprise German Decision Boosts Jardiance Pricing Potential
Boehringer Ingelheim/Lilly’s Jardiance has become one of the first of the newer antidiabetic agents to be viewed favorably by Germany's health technology assessment body, the G-BA. The surprise ruling paves the way for favorable pricing discussions.